YBX1 Expression Marks Proliferative Tumour States with Context-Dependent Genomic Instability: A Pan-Cancer Analysis
International Journal of Molecular Sciences · 13.05.2026 · 27 (10) · 4340
DOI: 10.3390/ijms27104340 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.05.2026. Verfasst von Selena Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine, University of Otago, Dunedin 9016, New Zealand. Hauptthemen laut MEDLINE: Y-Box-Binding Protein 1, Genomic Instability, Neoplasms, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council New Zealand, Health Research Council of New Zealand, Maurice Phyllis & Paykel Trust.
Abstract (Originalsprache)
Y-box binding protein 1 (YB-1; encoded by YBX1) is a multifunctional DNA- and RNA-binding protein implicated in cell cycle regulation, DNA repair, stress adaptation, and therapy resistance. Elevated YBX1 expression has been associated with aggressive disease across multiple cancer types; however, its pan-cancer genomic and clinical correlates, and the extent to which these reflect proliferative activity versus genomic instability, remain incompletely defined. Here, we performed an integrative pan-cancer analysis across 53 independent datasets spanning 33 tumour types, incorporating transcriptomic (YBX1 mRNA), proteomic (RPPA), genomic, and clinical data. We found that YBX1 is rarely altered at the genomic level, whereas its mRNA expression is highly variable within tumour cohorts. Tumours with high YBX1 mRNA expression consistently exhibited conserved transcriptional programmes enriched for cell cycle, mitotic, RNA processing, and signalling pathways, patterns that were also reflected at the protein level by concordant pathway associations with elevated YB-1 abundance. These molecular features co-occurred with clinicopathological characteristics indicative of aggressive disease. High YBX1 mRNA expression was associated with increased mutation burden, chromosomal alteration burden, hypoxia, and homologous recombination deficiency at the pan-cancer level, with similar molecular associations observed in tumours stratified by elevated YB-1 protein levels. The association between YBX1 expression and chromosomal alteration burden was largely attenuated after accounting for proliferative activity, particularly G2/M-associated transcriptional programmes used as a proxy for mitotic activity. While the relationship with mutation burden was heterogeneous across tumour types, this pattern suggests that links between YBX1 expression and chromosomal instability primarily reflect shared proliferative and mitotic tumour biology rather than an independent genomic instability programme. Clinically, high YBX1 mRNA expression was associated with advanced disease stage, higher histologic grade, reduced progression-free survival, and poorer overall survival. Elevated YB-1 protein levels were also associated with advanced disease stage and poorer survival outcomes and demonstrated a similar, although non-significant, directional trend with histologic grade. Collectively, these findings demonstrate that elevated YBX1 expression marks proliferative and clinically aggressive tumour states within which genomic instability-related features arise in a context-dependent manner, providing a clarified pan-cancer framework for interpreting YB-1-associated tumour biology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Molecular Medicine, University of Otago, Dunedin 9016, New Zealand.
- Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland 1142, New Zealand.
- Department of Obstetrics and Gynaecology, University of Otago, Christchurch 8011, New Zealand.
- School of Pharmacy and Biomedical Sciences, The University of Waikato Te Whare Wananga o Waikato, Hamilton 3240, New Zealand.
ORCID-Profile: Debina Sarkar, Makhdoom Sarwar, Aaron Jeffs, Glen Reid, Antony Braithwaite, Sunali Mehta
Förderung
- Health Research Council New Zealand
- Health Research Council of New Zealand
- Maurice Phyllis & Paykel Trust
- Maurice Phyllis and Paykel Trust, New Zealand
Zitieren
APA
Wang, S., Shafaei Pishabad, Z., Sarkar, D., Bhandarkar, A. A., Sarwar, M., Jeffs, A., Reid, G., Braithwaite, A., & Mehta, S. (2026). YBX1 Expression Marks Proliferative Tumour States with Context-Dependent Genomic Instability: A Pan-Cancer Analysis. International Journal of Molecular Sciences, 27(10), 4340. https://doi.org/10.3390/ijms27104340
Vancouver
Wang S, Shafaei Pishabad Z, Sarkar D, Bhandarkar AA, Sarwar M, Jeffs A, et al. YBX1 Expression Marks Proliferative Tumour States with Context-Dependent Genomic Instability: A Pan-Cancer Analysis. International Journal of Molecular Sciences. 2026;27(10):4340. doi:10.3390/ijms27104340
BibTeX
@article{Wang2026,
author = {Wang, Selena and Shafaei Pishabad, Zahra and Sarkar, Debina and Bhandarkar, Apeksha Arun and Sarwar, Makhdoom and Jeffs, Aaron and Reid, Glen and Braithwaite, Antony and Mehta, Sunali},
title = {YBX1 Expression Marks Proliferative Tumour States with Context-Dependent Genomic Instability: A Pan-Cancer Analysis},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {10},
pages = {4340},
doi = {10.3390/ijms27104340}
}
EUVIMED